MaxCyte, Inc. Grant of Options (9370E)

TIDMMXCT TIDMMXCR

RNS Number : 9370E

MaxCyte, Inc.

15 February 2018

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Maryland, USA, 15 February 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that it granted options, effective February 12, 2018, over a total of 40,900 options of its common stock in the Company ("Common Stock") to Richard Douglas, Non-Executive Director of the Company ("Option Grant").

The Option Grant vests ratably on a monthly basis following grant over 48 months. The Option Grant has an exercise period of 10 years from date of grant, at which time they will expire. The Option Grant is effective February 12, 2018, at an exercise price of 251.00p per option.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
====  ===================================================================== 
 a)    Name                              Richard Douglas 
====  ================================  =================================== 
 2     Reason for the notification 
====  ===================================================================== 
 a)    Position/status                   Non-Executive Director and PDMR 
====  ================================  =================================== 
 b)    Initial notification/Amendment    Initial notification 
====  ================================  =================================== 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
====  ===================================================================== 
 a)    Name                              MaxCyte, Inc. 
====  ================================  =================================== 
 b)    LEI                               54930053YHXULRFCU991 
====  ================================  =================================== 
 4     Details of the transaction(s): section to 
        be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
====  ===================================================================== 
 a)    Description                       Grant of options over Share 
        of the financial                  of Common Stock 
        instrument, 
        type of instrument 
====  ================================  =================================== 
 b)    Identification                    US57777K1060 
        Code 
====  ================================  =================================== 
 c)    Nature of                         Grant of options to a PDMR 
        the transaction 
====  ================================  =================================== 
 d)    Price(s) and                      Price(s)             Volume(s) 
        volume(s) 
====  ================================  ====================  ============= 
   251.00 pence                                               40,900 
  ==========================================================  ============= 
 e)    Aggregated                        N/A (Single transaction) 
        information 
        - Aggregated 
        volume 
        - Price 
====  ================================  =================================== 
 f)    Date of the                       12 February 2018 
        transaction 
====  ================================  =================================== 
 g)    Place of the                      Outside a trading venue 
        transaction 
====  ================================  =================================== 
 

For further information, please contact:

 
 MaxCyte Inc. 
 Doug Doerfler, Chief Executive 
  Officer 
  Ron Holtz, Chief Financial 
  Officer                                [phone] 
 
   Nominated Adviser and Broker 
   Panmure Gordon 
 Freddy Crossley (Corporate 
  Finance) 
  Ryan McCarthy 
  Tom Salvesen (Corporate Broking)       [phone] 
 
   Financial PR Adviser 
   Consilium Strategic Communications 
 Mary-Jane Elliott                       [phone] 
  Chris Welsh                             [e-mail] 
  Suki Virji 
 

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering enabling technology to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery technology, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This technology allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering enabling technology is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid

tumours where existing CAR-T approaches face significant challenges.   For more information, visit http://www.maxcyte.com/. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEAFALFLPPEAF

(END) Dow Jones Newswires

February 15, 2018 02:01 ET (07:01 GMT)